Skip to content
Topical BRAF-inhibiting Gel Controls Acneiform Rash in Patients with Colorectal Cancer Treated with EGFR-inhibition

Topical BRAF-inhibiting Gel Controls Acneiform Rash in Patients with Colorectal Cancer Treated with EGFR-inhibition

Get the podcast

An interview with: Anisha B Patel MD, Associate Professor of Dermatology, Division of Internal Medicine, MD Anderson Cancer Center, Houston TX CHICAGO, USA—Acneiform rash toxicities caused by anti- ep

The Audio Journal of Oncology

An interview with:

Anisha B Patel MD, Associate Professor of Dermatology, Division of Internal Medicine, MD Anderson Cancer Center, Houston TX

CHICAGO, USA—Acneiform rash toxicities caused by anti- epidermal growth factor receptor (EGFR) therapies were markedly reduced among patients with colorectal cancer in a double-blind placebo-controlled, randomized phase two clinical trial that assessed the efficacy of a topical BRAF inhibitor gel designed to treat these skin lesions without affecting cancer treatment.

The results were presented at the 2025 Annual Meeting of the American Association for Cancer Research (AACR).

First author of the study, Anisha Patel MD, Associate Professor of Dermatology at the MD Anderson Cancer Center in Houston Texas, gave Audio Journal of Oncology correspondent Peter Goodwin more details about the findings

AACR Abstract Title:

“A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies”

Next in AACR 2025

All 14 interviews

Interview 13 of 14

RAS Inhibitor Zoldonrasib Brings Clinical Benefit in Patients with G12D Mutated Non-Small Cell Advanced Lung Cancer

RAS Inhibitor Zoldonrasib Brings Clinical Benefit in Patients with G12D Mutated Non-Small Cell Advanced Lung Cancer

An interview with: Kathryn C Arbour MD, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York USA And: Ryan B Corcoran MD PhD, Massachusetts General Cancer Center, Associate Pr

30 April 2025
12 min

Related Episodes

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?

SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

10 Nov 2026
10 min
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

4 Jun 2026
11 min
Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma

Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma

BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca

21 May 2026
11 min